WO2006014683A3 - Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform - Google Patents

Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform Download PDF

Info

Publication number
WO2006014683A3
WO2006014683A3 PCT/US2005/025656 US2005025656W WO2006014683A3 WO 2006014683 A3 WO2006014683 A3 WO 2006014683A3 US 2005025656 W US2005025656 W US 2005025656W WO 2006014683 A3 WO2006014683 A3 WO 2006014683A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycoform
immunoglobulins
predominantly
relates
present
Prior art date
Application number
PCT/US2005/025656
Other languages
French (fr)
Other versions
WO2006014683A2 (en
Inventor
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Original Assignee
Glycofi Inc
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycofi Inc, Tillman U Gerngross, Huijuan Li, Stefan Wildt filed Critical Glycofi Inc
Priority to EP05790299A priority Critical patent/EP1771477A2/en
Priority to AU2005269763A priority patent/AU2005269763A1/en
Priority to JP2007522676A priority patent/JP2008515772A/en
Priority to CA002573842A priority patent/CA2573842A1/en
Publication of WO2006014683A2 publication Critical patent/WO2006014683A2/en
Publication of WO2006014683A3 publication Critical patent/WO2006014683A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Gal2GlcNAc2Man3GlcNAc2 lacking fucose.
PCT/US2005/025656 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform WO2006014683A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05790299A EP1771477A2 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform
AU2005269763A AU2005269763A1 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a Gal2GlcNac2Man3GlcNac2 glycoform
JP2007522676A JP2008515772A (en) 2004-07-21 2005-07-19 Immunoglobulin predominantly containing Gal2GlcNAc2Man3GlcNAc2 glycoform
CA002573842A CA2573842A1 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59003004P 2004-07-21 2004-07-21
US59005204P 2004-07-21 2004-07-21
US60/590,030 2004-07-21
US60/590,052 2004-07-21

Publications (2)

Publication Number Publication Date
WO2006014683A2 WO2006014683A2 (en) 2006-02-09
WO2006014683A3 true WO2006014683A3 (en) 2006-06-08

Family

ID=35502713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025656 WO2006014683A2 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform

Country Status (5)

Country Link
EP (1) EP1771477A2 (en)
JP (1) JP2008515772A (en)
AU (1) AU2005269763A1 (en)
CA (1) CA2573842A1 (en)
WO (1) WO2006014683A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102333872B (en) * 2009-02-25 2014-07-09 默沙东公司 Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
NZ576032A (en) 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
CA2725947A1 (en) 2008-05-30 2009-12-03 Glycofi, Inc. Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US8458171B2 (en) 2009-01-30 2013-06-04 Google Inc. Identifying query aspects
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2741769B1 (en) * 2011-08-10 2019-01-02 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated antibodies
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CN105263319A (en) 2013-02-13 2016-01-20 法国化学与生物科技实验室 Proteins with modified glycosylation and methods of production thereof
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003056914A1 (en) * 2001-12-27 2003-07-17 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003056914A1 (en) * 2001-12-27 2003-07-17 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOBROWICZ P ET AL: "Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose", GLYCOBIOLOGY, IRL PRESS,, GB, vol. 14, no. 9, 9 June 2004 (2004-06-09), pages 757 - 766, XP002354412, ISSN: 0959-6658 *
HAMILTON S R ET AL: "Production of complex human glycoproteins in yeast", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 301, no. 5637, 29 August 2003 (2003-08-29), pages 1244 - 1246, XP002267832, ISSN: 0036-8075 *
ROUTIER FRANCOISE H ET AL: "The glycosylation pattern of a humanized IgGI antibody (D1.3) expressed in CHO cells", GLYCOCONJUGATE JOURNAL, vol. 14, no. 2, 1997, pages 201 - 207, XP002375244, ISSN: 0282-0080 *
SCHWIENTEK TILO ET AL: "Golgi localization and in vivo activity of a mammalian glycosyltransferase (human beta-1,4-galactosyltransferase) in yeast", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 7, 1996, pages 3398 - 3405, XP002375245, ISSN: 0021-9258 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8883483B2 (en) 2000-06-28 2014-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
CN102333872B (en) * 2009-02-25 2014-07-09 默沙东公司 Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris

Also Published As

Publication number Publication date
JP2008515772A (en) 2008-05-15
AU2005269763A1 (en) 2006-02-09
EP1771477A2 (en) 2007-04-11
WO2006014683A2 (en) 2006-02-09
CA2573842A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2006014683A3 (en) Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform
WO2006071856A3 (en) Immunoglobulins comprising predominantly a man5glcnac2 glycoform
WO2006066568A3 (en) Antibody
WO2008094538A3 (en) Regulatory t cell epitopes, compositions and uses thereof
WO2007147122A3 (en) Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
IL184152A (en) Monoclonal antibodies against nkg2a, compositions comprising the same, uses thereof for the manufacture of medicaments, methods for their production and methods employing said antibodies
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2006023420A3 (en) Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2008091798A3 (en) Optimized ca9 antibodies and methods of using the same
WO2008022152A3 (en) Optimized antibodies that target cd19
WO2005074970A3 (en) Neuroprotective dietary supplement
IL222756A0 (en) Antibodies and antigen-binding fragments thereof that bind to a sclerostin polypeptide, compositions containing the same and methods for the production thereof
WO2006104989A3 (en) Altered antibody fc regions and uses thereof
WO2006050280A3 (en) Anti-respiratory syncytial virus antibodies, antigens and uses thereof
WO2007008583A3 (en) Improved protein expression comparison assay results and applications
WO2007050569A3 (en) Polypeptide multilayer films and methods
WO2008046642A3 (en) Coated implant
EP1647596A4 (en) Monoclonal antibody against platelet membrane glycoprotein vi
AU2003233992A1 (en) Functional element for attaching to a sheet metal part, composite component produced from said element and method for attaching the functional element to a sheet metal part
WO2006014726A3 (en) Immunoglobulins comprising predominantly a man5glcnac2 glycoform
WO2006019955A3 (en) Antiviral methods and compositions
WO2004004639A3 (en) A novel stable formulation
WO2004075021A3 (en) Molecular modeling methods
FR2855557B1 (en) TUYERE COMPONENT WITH INCREASED LIFETIME FOR AIRCRAFT TURBOMOTORS.
NL1021490A1 (en) Process for the preparation of a fluoropolymer.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2573842

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005790299

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007522676

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580024664.0

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005269763

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1206/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005269763

Country of ref document: AU

Date of ref document: 20050719

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005269763

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005790299

Country of ref document: EP